254
Participants
Start Date
April 30, 2012
Primary Completion Date
March 31, 2014
Study Completion Date
June 30, 2014
Eslicarbazepine Acetate tablets
The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
Hradec Králové
Kroměříž
Prague
Aalborg
Arhus C
Copenhagen
Dianalund
Esbjerg
Glostrup Municipality
Holstebro
Roskilde
Sønderborg
Vejle
Altkirch
Armentières
Bergerac
Biarritz
Chaumont
Cholet
Gap
Nice
Nîmes
Paris
Perpignan
Rueil-Malmaison
Sarreguemines
Toulon
Altenholz
Asperg
Augsburg
Bad Berka
Bad Langensalza
Berlin
Beuel
Bielefeld
Bochum
Bockhorn
Buxtehude
Cologne
Dortmund
Erbach im Odenwald
Erlangen
Etville
Gelsenkirchen
Gera
Greiz
Grevenbroich
Guelders
Hamburg
Hamm
Heilbad Heiligenstadt
Herdecke
Hildesheim
Hof
Ilmenau
Itzehoe
Kamp-Lintfort
Kirchen (Sieg)
Königsbrück
Leipzig
Leverkusen
Lohr a. Main
Ludwigsburg
Mannheim
Mittweida
München
Oranienburg
Osnabrück
Quakenbrück
Rathenow
Salzgitter
Schirgiswalde-Kirschau
Schorndorf
Schwäbisch Gmünd
Senftenberg
Solingen
Stuttgart
Troisdorf (Sieglar)
Waiblingen
Wesel
Westerstede
Wilhelmshaven
Wolfsburg
Würzburg
Dooradoyle/ Co. Limerick
Dublin
Bergen
Molde
Oslo
Skien
Angered
Helsingborg
Kungsbacka
Linköping
Stockholm / Saint Goran
Birmingham
Dundee
London
Middlesbrough
Newport
Romford
Salford
Stoke-on-Trent
Telford
Torquay, Devon
Truro
Eisai Inc.
INDUSTRY